GoodRx delivered a solid financial quarter in Q2 2025, with total revenue increasing 1% year-over-year to $203.1 million. The company achieved a net income of $12.8 million and an Adjusted EBITDA of $69.4 million, demonstrating continued year-over-year Adjusted EBITDA Margin growth. While facing headwinds in prescription transactions and subscriptions, the Pharma Manufacturer Solutions segment showed strong growth, increasing 32% year-over-year.

GoodRx reported a 3% increase in revenue and a significant improvement in net income for the first quarter of 2025 compared to the prior year, exceeding previous Adjusted EBITDA margin guidance. The company maintained its full-year 2025 revenue guidance and raised its Adjusted EBITDA expectations.

GoodRx reported Q4 2024 revenue of $198.6 million and net income of $6.7 million. The company exited the quarter with over 7 million consumers of prescription-related offerings.

GoodRx reported an 8% increase in revenue to $195.3 million and a net income of $4.0 million for Q3 2024, compared to a net loss of $38.5 million in the same period last year. The growth was primarily driven by a 77% increase in pharma manufacturer solutions revenue and a 4% increase in prescription transactions revenue.

GoodRx reported a 6% increase in revenue to $200.6 million for Q2 2024. Net income was $6.7 million, compared to $58.8 million in the prior year, impacted by a prior year income tax benefit. The company exited the quarter with over 7 million consumers of prescription-related offerings.

GoodRx's Q1 2024 results showed positive momentum with revenue increasing by 8% to $197.9 million. The company is focused on reigniting growth and strengthening its business model, aiming to return to being a 'Rule of 40' company.

GoodRx's Q4 2023 results showed a 7% increase in revenue and adjusted revenue to $196.6 million. The company reported a net loss of $25.9 million, while adjusted EBITDA reached $57.3 million. The company exited the quarter with over 7 million consumers of prescription-related offerings.

GoodRx's third quarter 2023 results showed a revenue of $180.0 million, a decrease of 4% compared to the previous year. Adjusted Revenue increased by 1% to $190.0 million. The company reported a net loss of $38.5 million and an Adjusted EBITDA of $53.5 million.

GoodRx's second quarter 2023 results exceeded expectations, with revenue at $189.7 million. Prescription transactions revenue and volume returned to year-over-year growth. The company is focused on rebuilding momentum financially and operationally, aiming for growth in 2024 and beyond.

GoodRx's total revenue decreased by 10% to $184.0 million compared to $203.3 million. Net loss was $3.3 million compared to a net income of $12.3 million. Adjusted EBITDA was $53.2 million compared to $64.7 million.

GoodRx reported Q4 2022 total revenue of $184.1 million, exceeding guidance. Subscription revenue grew 42% year-over-year. Over 7 million Americans used GoodRx for their healthcare needs in the fourth quarter.

GoodRx's Q3 2022 earnings report revealed a total revenue of $187.3 million, surpassing previous guidance. Despite a net loss of $41.71 million, the company saw double-digit growth in subscription and pharma manufacturer solutions platforms. The company is prioritizing profitability and cash flow.

GoodRx released its second quarter 2022 financial results. The management hosted a conference call and webcast to discuss the results and the Company’s business outlook.

GoodRx released its first quarter 2022 financial results, highlighting its performance as a leading consumer-focused digital healthcare platform.

GoodRx released its fourth quarter and full year 2021 financial results.

GoodRx released its third quarter 2021 financial results.

GoodRx released its second quarter 2021 financial results.

GoodRx Holdings Inc. released its first quarter 2021 financial results.

GoodRx released its fourth quarter and full year 2020 financial results.

GoodRx released its third quarter 2020 financial results.